GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn’t be overlooked as a long-term

Posted on May 18, 2011 at 06:29 AM EDT

Isis Pharmaceuticals Inc. (ISIS) ended the first quarter, with nearly $427 million in cash. Revenue for the three months ended March 31, 2011 was $21.1 million, compared to $29.9 million for the same period in 2010. Isis Pharmaceuticals earned a $3 million payment from GlaxoSmithKline (GSK) to discover and develop drugs to treat rare and [...]